Earnings ·
Azenta, Inc. reported financial results for the third quarter ended June 30, 2026, with revenue from continuing…
AZTAAzenta, Inc.
Azenta, Inc. reported financial results for the third quarter ended June 30, 2026, with revenue from continuing operations reaching $161 million, a 12% increase year over year. Organic growth was 9%, driven by Sample Management Solutions ($88 million) and Multiomics ($73 million). The company reported a diluted EPS of $(0.03) from continuing operations and total diluted EPS of $0.05. Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 11.4%. Azenta updated its full-year fiscal 2026 guidance, now expecting total reported revenue between $613 million and $618 million and Adjusted EBITDA between $59 million and $62 million. The company ended the quarter with $529 million in cash and liquidity. As of June 30, 2026, Azenta had repurchased 2.3 million shares for $50 million under its 2025 share repurchase program. Azenta is a provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, and academic institutions.